All Stories

  1. The Kinetics and Interplay of Thrombin Inhibition by Four Plasma Protease Inhibitors
  2. Modelling the effects of 4-factor prothrombin complex concentrate for the management of factor Xa-associated bleeding
  3. Emicizumab promotes factor Xa generation on endothelial cells
  4. Ultrasoft platelet-like particles stop bleeding in rodent and porcine models of trauma
  5. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants
  6. Inhalation of an RNA aptamer that selectively binds extracellular histones protects from acute lung injury
  7. Thrombin generation and implications for hemophilia therapies: A narrative review
  8. Analytical Validation and Quality Control/Quality Assurance Practices for Improved Rigor and Reproducibility of Biochemical Assays in Orthopaedic Research
  9. A commentary on “A rapid, sensitive and specific assay to measure TF activity based on chromogenic determination of thrombin generation”
  10. Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors
  11. Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding
  12. Trauma-induced coagulopathy
  13. Cell-Mediated Hemostasis
  14. Platelet-like particles improve fibrin network properties in a hemophilic model of provisional matrix structural defects
  15. EPCR knockout: inflaming the discussion
  16. Nanosilver composite pNIPAm microgels for the development of antimicrobial platelet‐like particles
  17. A unique protein kinase C-dependent pathway for tissue factor downregulation in pericytes
  18. Regulation of Hemostasis and Thrombosis
  19. The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review
  20. The next best thing in factor VIIa
  21. Human platelets express endothelial protein C receptor, which can be utilized to enhance localization of factor VIIa activity
  22. The Tissue Factor Pathway and Wound Healing
  23. Differentiating between cold agglutinins and rouleaux: a case series of seven patients
  24. Impact of Non–Vitamin K Antagonist Oral Anticoagulants From a Basic Science PerspectiveHighlights
  25. Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis
  26. No association between donor age and recipient outcomes: transfusion of plasma in patients undergoing coronary artery bypass grafting surgery
  27. An activated factor VII variant with enhanced tissue factor-independent activity speeds wound healing in a mouse hemophilia B model
  28. Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
  29. Cell-Mediated Hemostasis
  30. Coated platelet assay: a feasible approach to a complicated science
  31. Coated platelets and severe haemophilia A bleeding phenotype: Is there a connection?
  32. Coagulation in Liver Disease
  33. Novel oral anticoagulants and reversal agents: Considerations for clinical development
  34. Reversal of Dabigatran Effects in Models of Thrombin Generation and Hemostasis by Factor VIIa and Prothrombin Complex Concentrate
  35. Fibrinogen-Coated Nanospheres Prevent Thrombocytopenia-Related Bleeding
  36. 161: Effect of antifibrinolytic drugs on in vitro clot formation among peripartum women
  37. Reversing targeted oral anticoagulants
  38. Hemostasis: Old System, New Players, New Directions
  39. A mouse bleeding model to study oral anticoagulants
  40. Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology
  41. Theories of Blood Coagulation: Basic Concepts and Recent Updates
  42. Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence?
  43. Progressive improvement in wound healing with increased therapy in haemophilia B mice
  44. Superactivated Platelets: Thrombus Regulators, Thrombin Generators, and Potential Clinical Targets
  45. Bleeding risk in warfarinized patients with a therapeutic international normalized ratio: the effect of low factor IX levels
  46. Practical coagulation for the blood banker
  47. Low intensity laser therapy speeds wound healing in hemophilia by enhancing platelet procoagulant activity
  48. Mechanisms and monitoring of bypassing agent therapy
  49. The clotting system - a major player in wound healing
  50. Consequences of intra-articular bleeding in haemophilia: science to clinical practice and beyond
  51. Hemostatic properties of the FVIIa analog NN1731
  52. The multiple roles of tissue factor in wound healing
  53. Hypothesis: Hyperhomocysteinemia is an indicator of oxidant stress
  54. Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin
  55. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity
  56. Prophylactic correction of the international normalized ratio in neurosurgery: a brief review of a brief literature
  57. Editorial: International normalized ratio
  58. Inflammation does not predispose to bleeding in hemophilia
  59. Heparins: Clinical Use and Laboratory Monitoring
  60. Wound healing in haemophilia - breaking the vicious cycle
  61. Wound healing in hemophilia B mice and low tissue factor mice
  62. Platelet binding and activity of recombinant factor VIIa
  63. Regulation of Hemostasis and Thrombosis
  64. Contributors
  65. Heparin cofactor II in atherosclerotic lesions from the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study
  66. The Influence of Hemophilia on Wound Healing.
  67. Platelet functions beyond hemostasis
  68. Synergistic effect of aptamers that inhibit exosites 1 and 2 on thrombin
  69. A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell-based model of thrombin generation
  70. Tissue Factor in Brain Is Not Saturated With Factor VIIa: Implications for Factor VIIa Dosing in Intracerebral Hemorrhage
  71. Celecoxib does not delay cutaneous wound healing in haemophilia B mice
  72. The Coagulation Cascade in Cirrhosis
  73. Dysregulation of Hemostasis by Cancer
  74. FVIIa: you've come a long way, baby!
  75. Animal models of bleeding and tissue repair
  76. Alterations of Fibrinogen Structure in Human Disease
  77. Some things I thought I knew about tissue factor that turn out to be wrong
  78. Perivascular tissue factor is down-regulated following cutaneous wounding: implications for bleeding in hemophilia
  79. Hypercoagulation and thrombophilia in liver disease
  80. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B
  81. Tissue factor around dermal vessels has bound factor VII in the absence of injury
  82. Review article: the prothrombin time test as a measure of bleeding risk and prognosis in liver disease
  83. Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes
  84. Coagulation 2006: A Modern View of Hemostasis
  85. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia
  86. Fathers of modern coagulation
  87. Cutaneous wound healing is impaired in hemophilia B
  88. Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs
  89. Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia
  90. A Cell-Based Model of Thrombin Generation
  91. Modification of Fibrinogen by Homocysteine Thiolactone Increases Resistance to Fibrinolysis:  A Potential Mechanism of the Thrombotic Tendency in Hyperhomocysteinemia †
  92. Why Are Young College Women Not Using Condoms? Their Perceived Risk, Drug Use, and Developmental Vulnerability May Provide Important Clues to Sexual Risk
  93. What Does It Take to Make the Perfect Clot?
  94. Coagulation disorders and hemostasis in liver disease: Pathophysiology and critical assessment of current management
  95. High dose factor VIIa improves clot structure and stability in a model of haemophilia B
  96. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft
  97. Platelet Heterogeneity: Variation in Coagulation Complexes on Platelet Subpopulations
  98. One more way that mice and men are different
  99. Rethinking the Coagulation Cascade
  100. The Cellular Basis of Traumatic Bleeding
  101. New Concepts in Managing Catastrophic Bleeding: A Combat Perspective
  102. A Systematic Evaluation of the Effect of Temperature on Coagulation Enzyme Activity and Platelet Function
  103. UNDERSTANDING AND MANAGING COAGULOPATHIC BLEEDING
  104. Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system
  105. Differences in the metabolic response to exogenous homocysteine in juvenile and adult rabbits
  106. Safety profile of recombinant factor VIIa
  107. The Potential Role of Factor VIIa in Transfusion Medicine
  108. Laboratory Monitoring of High-Dose Factor VIIa Therapy
  109. The Effect of Temperature and pH on the Activity of Factor VIIa: Implications for the Efficacy of High-Dose Factor VIIa in Hypothermic and Acidotic Patients
  110. Localization of heparin cofactor II in injured human skin: a potential role in wound healing
  111. A cell-based model of coagulation and the role of factor VIIa
  112. Remodeling the Blood Coagulation Cascade
  113. Protease-Activated Receptor-2 Signaling Triggers Dendritic Cell Development
  114. New Insights into the Coagulation System and Implications for New Therapeutic Options with Recombinant Factor VIIa
  115. Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk
  116. Expanding uses of high-dose factor VIIa
  117. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia
  118. The action of high-dose factor Vlla (FVIIa) in a cell-based model of hemostasis
  119. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  120. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  121. Analyzing fibrin clot structure using a microplate reader
  122. Platelets and Thrombin Generation
  123. Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces
  124. FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia
  125. Circulating and binding characteristics of wild-type factor IX and certain Gla domain mutants in vivo
  126. Coagulation Factor Interaction with Platelets
  127. Generation of Species Cross-reactive Aptamers Using “Toggle” SELEX
  128. Exposure of Mice to Topical Bovine Thrombin Induces Systemic Autoimmunity
  129. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis
  130. High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system
  131. Hemophilia Care in the New Millennium
  132. Inhibition of human and pig thrombin by a high-affinity nuclease-resistant RNA aptamer
  133. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations
  134. Deencryption of Cellular Tissue Factor Is Independent of Its Cytoplasmic Domain
  135. Platelets induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic rat liver
  136. The Factor VII-Platelet Interplay: Effectiveness of Recombinant Factor VIIa in the Treatment of Bleeding in Severe Thrombocytopathia
  137. Links Between the Immune and Coagulation Systems: How Do "Antiphospholipid Antibodies" Cause Thrombosis?
  138. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations
  139. Platelets from Thrombocytopenic Ponies Acutely Infected with Equine Infectious Anemia Virus Are Activated in Vivo and Hypofunctional
  140. Chemistry and Biology of Serpins Edited by Frank C. Church, Dennis D. Cunningham, David Ginsburg, Maureane Hoffman, Stuart R. Stone, and Douglas M. Tollefsen. Plenum Press:  New York. 1997. xvii + 358 pp. $95.00. ISBN 0-306-45698-2.
  141. A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer
  142. Platelet activity of high-dose factor VIIa is independent of tissue factor
  143. From antiphospholipid syndrome to antibody-mediated thrombosis
  144. Chemistry and Biology of Serpins
  145. Variability in platelet procoagulant activity in healthy volunteers
  146. Culturing unactivated monocytes
  147. Cellular Interactions in Hemostasis
  148. Thrombin Enhances Monocyte Secretion of Tumor Necrosis Factor and Interleukin-1 Beta By Two Distinct Mechanisms
  149. The Monocyte Monolayer Assay: A Noninvasive Technique for Predicting the Severity of in Utero Hemolysis
  150. Platelet procoagulant complex assembly in a tissue factor-initiated system
  151. Reticulated platelet counts in patients undergoing autologous bone marrow transplantation: An aid in assessing marrow recovery
  152. Heparin cofactor II and thrombin
  153. Platelets contain releasable coagulation factor IX antigen
  154. Platelets contain releasable coagulation factor IX antigen
  155. Platelet activation in patients with thrombotic thrombocytopenic purpura
  156. A Rapid Method to Isolate Platelets from Human Blood by Density Gradient Centrifugation
  157. The effects of heparin cofactor II-derived chemotaxins on neutrophil actin conformation and cyclic AMP levels
  158. Antibody-Coated Erythrocytes Induce Secretion of Tumor Necrosis Factor by Human Monocytes: A Mechanism for the Production of Fever by Incompatible Transfusions
  159. The Effect of Alpha2Macroglobulin-Proteinase Complexes on Macrophage IA Expression in Vivo
  160. PDGF-stimulated fibroblast proliferation is enhanced synergistically by receptor-recognized ?2-Macroglobulin
  161. Variability in the Fibrinogen and Von Willebrand Factor Content of Cryoprecipitate: Implications for Reducing Donor Exposure
  162. Effect of interferon-γ and human α2-macroglobulin on peritoneal macrophage morphology and Ia antigen expression
  163. Production of chemotactic peptides by neutrophil degradation of heparin cofactor II
  164. Comparison of the effects of IL-1α and TNF-α on phagocyte accumulation and murine antibacterial immunity
  165. Alpha-Macroglobulin Secreted by Alveolar Macrophages Serves as a Binding Protein for a Macrophage-derived Homologue of Platelet-derived Growth Factor
  166. α 2Macroglobulin-proteinase complexes stimulate prostaglandin E2 synthesis by peritoneal macrophages
  167. Reduced trypsin-binding capacity of α2-macroglobulin in the peritoneal fluid of women with endometriosis: possible relevance to alterations in macrophase function**Supported by the Career Development Program of the Veterans Administration (M.H.); the J...
  168. The Effect of Fibrin Polymerization Inhibitors on Quantitative Measurements of Plasma Fibrinogen
  169. The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and α1-proteinase inhibitor
  170. α2-macroglobulin ‘fast’ forms inhibit superoxide production by activated macrophages
  171. Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages
  172. Production of superoxide anion by an nadph-oxidase from rat pulmonary macrophages
  173. Changes in Oxygen Consumption and Phagocytosis in Rat Pulmonary Macrophages Related to Animal Maturation
  174. Adaptation to hyperoxia in the neonatal rat: Kinetic parameters of the oxygen-mediated induction of lung superoxide dismutases, catalase and glutathione peroxidase